With the approval of frontline pembrolizumab monotherapy for advanced NSCLC with PD-L1 of 1% or above, how do you select who gets Chemo-IO versus pembro monotherapy if PD-L1 between 1-49%?
1 Answers
Mednet Member
Medical Oncology · University of Miami
Most patients with PDL1 1-49% should continue to be offered chemotherapy + IO and not pembrolizumab alone.
With the approval of frontline pembrolizumab monotherapy for advanced NSCLC with PD-L1 of 1% or above, how do you select who gets Chemo-IO versus pembro monotherapy if PD-L1 between 1-49%? | Mednet
